UroGen Pharma Ltd. Increase (Decrease) in Prepaid Expense and Other Assets
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$6.75M.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $4.86M, a 17.40% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.55M.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $67.00K, a 96.37% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $5.83M.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.44M.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$820.00K, a 122.61% decline from fiscal 2022.
- UroGen Pharma Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.63M, a 11.80% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.90M 10-Q · filed 2026-08-05 | $654.00K derived: sum of 3 quarters · filed 2026-08-05 | $721.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.86M 10-Q · filed 2026-05-06 | $7.41M derived: sum of 2 quarters · filed 2026-05-06 | $7.47M derived: sum of 3 quarters · filed 2026-05-06 | $6.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.62M derived: sum of 2 quarters · filed 2026-03-02 | $1.69M derived: sum of 3 quarters · filed 2026-08-05 | $5.83M 10-K · filed 2026-03-02 |
| 2025-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$861.00K derived: sum of 2 quarters · filed 2026-08-05 | $3.28M 10-Q · filed 2025-11-06 | -$1.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$928.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.21M 10-Q · filed 2026-08-05 | -$2.00M derived: sum of 3 quarters · filed 2026-08-05 | -$153.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.14M 10-Q · filed 2026-05-06 | -$1.07M derived: sum of 2 quarters · filed 2026-05-06 | $775.00K derived: sum of 3 quarters · filed 2026-05-06 | $2.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$3.36M derived: sum of 2 quarters · filed 2026-03-02 | -$1.65M derived: sum of 3 quarters · filed 2026-03-02 | -$1.44M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.56M derived: sum of 2 quarters · filed 2025-11-06 | $3.77M 10-Q · filed 2025-11-06 | -$1.99M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.93M 10-Q · filed 2025-08-07 | -$3.83M derived: sum of 3 quarters · filed 2025-08-07 | -$515.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $210.00K 10-Q · filed 2025-05-12 | -$5.55M derived: sum of 2 quarters · filed 2025-05-12 | -$2.23M derived: sum of 3 quarters · filed 2025-05-12 | -$1.66M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.44M derived: sum of 2 quarters · filed 2025-03-10 | -$1.86M derived: sum of 3 quarters · filed 2025-03-10 | -$820.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.89M derived: sum of 2 quarters · filed 2024-11-06 | $4.94M 10-Q · filed 2024-11-06 | $5.46M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.62M 10-Q · filed 2024-08-13 | $2.14M derived: sum of 3 quarters · filed 2024-08-13 | $2.29M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-13 | $1.57M derived: sum of 2 quarters · filed 2024-05-13 | $1.71M derived: sum of 3 quarters · filed 2024-05-13 | $2.87M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $668.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.83M derived: sum of 3 quarters · filed 2024-03-14 | $3.63M 10-K · filed 2024-03-14 |
| 2022-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.30M derived: sum of 2 quarters · filed 2023-11-14 | $3.10M 10-Q · filed 2023-11-14 | $4.47M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.96M 10-Q · filed 2023-08-10 | $4.32M derived: sum of 3 quarters · filed 2023-08-10 | $5.13M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-11 | $3.16M derived: sum of 2 quarters · filed 2023-05-11 | $3.97M derived: sum of 3 quarters · filed 2023-05-11 | $2.96M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.17M derived: sum of 2 quarters · filed 2023-03-24 | $1.16M derived: sum of 3 quarters · filed 2023-03-24 | $4.11M 10-K · filed 2023-03-24 |
| 2021-09-30 | $805.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$203.00K derived: sum of 2 quarters · filed 2022-11-10 | $2.75M 10-Q · filed 2022-11-10 | $1.82M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.94M 10-Q · filed 2022-08-11 | $1.01M derived: sum of 3 quarters · filed 2022-08-11 | $3.24M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.95M 10-Q · filed 2022-05-10 | $2.02M derived: sum of 2 quarters · filed 2022-05-10 | $4.25M derived: sum of 3 quarters · filed 2022-05-10 | $4.76M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.29M derived: sum of 2 quarters · filed 2022-03-21 | $1.81M derived: sum of 3 quarters · filed 2022-03-21 | $2.33M 10-K · filed 2022-03-21 |
| 2020-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.74M derived: sum of 2 quarters · filed 2021-11-15 | $3.26M 10-Q · filed 2021-11-15 | $3.13M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $517.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.03M 10-Q · filed 2021-08-04 | $909.00K derived: sum of 3 quarters · filed 2021-08-04 | $347.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $518.00K 10-Q · filed 2021-05-13 | $392.00K derived: sum of 2 quarters · filed 2021-05-13 | -$170.00K derived: sum of 3 quarters · filed 2021-05-13 | $871.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$688.00K derived: sum of 2 quarters · filed 2021-03-18 | $353.00K derived: sum of 3 quarters · filed 2021-03-18 | $394.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | -$562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $479.00K derived: sum of 2 quarters · filed 2020-11-09 | $520.00K 10-Q · filed 2020-11-09 | $531.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.08M 10-Q · filed 2020-08-10 | $1.09M derived: sum of 3 quarters · filed 2020-08-10 | $698.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $41.00K 10-Q · filed 2020-05-07 | $52.00K derived: sum of 2 quarters · filed 2020-05-07 | -$343.00K derived: sum of 3 quarters · filed 2020-05-07 | -$45.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$384.00K derived: sum of 2 quarters · filed 2020-03-02 | -$86.00K derived: sum of 3 quarters · filed 2020-03-02 | -$318.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | -$395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$97.00K derived: sum of 2 quarters · filed 2019-11-12 | -$329.00K 10-Q · filed 2019-11-12 | -$281.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $66.00K 10-Q · filed 2019-08-09 | $114.00K derived: sum of 3 quarters · filed 2020-03-02 | $320.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$232.00K 10-Q · filed 2019-05-09 | -$184.00K derived: sum of 2 quarters · filed 2020-03-02 | $22.00K derived: sum of 3 quarters · filed 2020-03-02 | $172.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $48.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $254.00K derived: sum of 2 quarters · filed 2020-03-02 | $404.00K derived: sum of 3 quarters · filed 2020-03-02 | $562.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $206.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $356.00K derived: sum of 2 quarters · filed 2018-11-13 | $514.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $150.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $308.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $158.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | -$739.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $737.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |